Cenicriviroc

Phase 3Small molecule

TTobira Therapeutics, Inc.

Cenicriviroc is one of 208 small molecule programs targeting Cognitive impairment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

207

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

HepatitisActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

FibrosisActive, not recruiting

COVID-19Active, not recruiting

Sclerosing CholangitisActive, not recruiting

Cognitive ImpairmentPhase 2

Active, not recruiting

HepatitisPhase 3

Active, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

FibrosisPhase 2

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Sclerosing CholangitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Cenicriviroc

TTobira Therapeutics, Inc.

Phase 3

3 2

Bnt162b2

BioNTech

Preclinical

29 3

Aldactone

Pfizer

Preclinical

1 4

Singulair

AstraZeneca

Preclinical

1 5

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 6

Blood Taken

HHospices Civils de Lyon

Preclinical

1 7

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 8

Selenium

SSWOG Cancer Research Network

Preclinical

1 9

Tpa

UUniversity of Florida

Preclinical

1 10

Immunosuppressive

Chiesi Farmaceutici S.p.A.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 2Active, not recruiting

COVID-19

NCT04488081

Clinical

Trials by Indication[1]

Hepatitis3 trials

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

Terminated·TTobira Therapeutics, Inc.·Phase 3·NCT03028740·1,778 enrolled

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

Completed·TTobira Therapeutics, Inc.·Phase 2·NCT02217475·289 enrolled

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Terminated·TTobira Therapeutics, Inc.·Phase 2·NCT03059446·167 enrolled

COVID-193 trials

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active, not recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT04488081·1,500 enrolled

Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients

Terminated·—·Phase 2·NCT04500418·45 enrolled

Immune Modulators for Treating COVID-19

Completed·DDaniel Benjamin·Phase 3·NCT04593940·1,971 enrolled

Age1 trial

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

Completed·TTobira Therapeutics, Inc.·Phase 1·NCT02684799·48 enrolled

Cognitive impairment1 trial

Effect of Cenicriviroc on HIV Neurocognitive Impairment

Completed·UUniversity of Hawaii·Phase 2·NCT02128828·20 enrolled

Moderate Hepatic Impairment1 trial

Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment

Completed·TTobira Therapeutics, Inc.·Phase 1·NCT02120547·31 enrolled

7 more indications

Sclerosing Cholangitis1 trial

PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis

Completed·TTobira Therapeutics, Inc.·Phase 2·NCT02653625·24 enrolled

Antiretroviral Treatment1 trial

Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

Completed·TTobira Therapeutics, Inc.·Phase 2·NCT01338883·143 enrolled

Fibrosis1 trial

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

Completed· Novartis logo

Novartis·Phase 2·NCT03517540·193 enrolled

Type 2 Diabetes Mellitus1 trial

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

Completed·TTobira Therapeutics, Inc.·Phase 2·NCT02330549·45 enrolled

Hepatic Impairment1 trial

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

Completed· AbbVie logo

AbbVie·Phase 1·NCT03376841·16 enrolled

Single Dose1 trial

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

Completed·TTobira Therapeutics, Inc.·Phase 1·NCT01827540·20 enrolled

Unspecified1 trial

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

Completed·TTobira Therapeutics, Inc.·Phase 1·NCT02342067·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Cenicriviroc. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cenicriviroc compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cenicriviroc. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tobira Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTobira Therapeutics, Inc.

Cenicriviroc

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Hepatitis3 trials

COVID-193 trials

Age1 trial

Cognitive impairment1 trial

Moderate Hepatic Impairment1 trial

Sclerosing Cholangitis1 trial

Antiretroviral Treatment1 trial

Fibrosis1 trial

Type 2 Diabetes Mellitus1 trial

Hepatic Impairment1 trial

Single Dose1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News